相关实验视频

Updated: Jul 2, 2025

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

贝佩多酸:降低脂质以预防心血管疾病

Michael Albosta¹, Jelani K Grant², Erin D Michos²

¹Internal Medicine Department, University of Miami Miller School of Medicine/Jackson Memorial Hospital, Miami, FL, USA.

Heart international

|February 29, 2024

概括

班佩多酸有效降低LDL-C,并减少高风险患者的心血管事件与他类药物不耐受. 这种非他类药物疗法为那些不能耐受他类药物的人提供了一个至关重要的替代方案,改善了动脉样硬化心血管疾病的预防.

科学领域:

心脏病学心脏病学
药理学药理学是指药理学的学科.
代谢疾病代谢疾病

背景情况:

动脉样性心血管疾病 (ASCVD) 的管理依赖于降低低密度脂蛋白胆固醇 (LDL-C).
类他类药物是第一线治疗,但高达30%的患者经历了不耐受,阻碍了LDL-C目标的实现.
感知到的他类药物不耐受性,包括nocebo效应,构成了重大的临床挑战.

研究的目的:

为了评估bempedoic酸,一个新的非他类脂类降低剂,在患者的他类不耐受性.
评估bempedoic酸在降低LDL-C和主要不良心血管事件 (MACE) 的有效性和安全性.

主要方法:

在CLEAR Outcomes试验中,加入了高风险患者,这些患者有他类药物不耐受性和升高的LDL-C (≥100 mg/dL).
孟佩多酸对降低LDL-C的作用单独和与ezetimibe结合进行了评估.
心血管结局,包括4组分MACE,在bempedoic酸和安慰剂之间进行了比较.

主要成果:

贝佩多酸在使用他类药物时降低了~18%的LDL-C,在不耐他类药物患者中降低了~21%,在使用ezetimibe时降低了~38%.
该试验显示,使用贝佩多酸的4组分MACE (HR 0.87) 与安慰剂相比减少了13%.
在心肌梗塞 (23%) 和冠状动脉复血管化 (19%) 中观察到显著的减少,在初级预防中获益更大.

结论:

班佩多酸是一种有效的非他类药物疗法,用于降低高风险患者的LDL-C和心血管结果,患者有他类药物不耐受.
该药物为需要进一步降低LDL-C的患者提供了宝贵的替代品,超出了他类药物治疗.
虽然与尿酸增加和胆病相关,但bempedoic酸在数值上显示了较少的肌痛和新发糖尿病事件.

关键词:

动脉样硬化心血管疾病.贝佩多酸是白酸的一种酸.预防心血管疾病和预防心血管疾病显而易见的结果试验结果降脂的降脂剂可以降低脂肪.脂质脂质脂质是一种低密度脂蛋白胆固醇是低密度的脂蛋白胆固醇.

更多相关视频

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...

Antihypertensive Drugs: Action of β1 Blockers

Antihypertensive Drugs: Action of β₁ Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...